Hepatic hydrothorax: About a hospital serie of 63 cases.

##plugins.themes.academic_pro.article.sidebar##

Published Sep 22, 2017
Download
pdf
Vol. 94 No. 12 (2016): Issue Dec 2016

##plugins.themes.academic_pro.article.main##

Leila Mouelhi
Oussama Daboussi
Nadia Cheffi
Kaouther El Jery
Yosra Said
Sana Khedher
Mohamed Salem
Radhouane Dabbèche
Fatma Houissa
Taoufik Najjar

Abstract

Background: Hepatic hydrothorax is a less common complication of cirrhosis with an estimated prevalence of 10- 15%. In the vast majority of cases, ascites are also present but significant pleural effusion may develop in patients without ascites. Hepatic hydrothorax is associated with cirrhosis whatever its etiology. The prognosis of hepatic hydrothorax remains unclear and is closely related to available therapeutic options.

The aim of our study is to determine the prevalence of hydrothorax in cirrhotic patients, detail its clinical and therapeutic characteristics, and study the evolutive profile of cirrhotic patients with hydrothorax by comparing it to those without hydrothorax. We also search predictive factors of development of this complication in cirrhotic patients.

Methods: We conduct a retrospective and case-control study including 63 cirrhotic patients with hepatic hydrothorax hospitalized in gastroenterology department of Charles Nicolle hospital of Tunis, during a period of fiveteen years, from January 2000 to January 2015.

Results: The prevalence of hydrothorax was 14.5%. The mean age was 62 ± 14 years (range, 22- 86 years). The sex ratio H/F was 1.52. Hepatic hydrothorax was symptomatic in 35 patients. It was right-sided in 60%, left-sided in 24% and bilateral in 16% of cases. Hydrothorax was on average size abundance in 54% of cases. It was transsudatif in 52.5% of cases. Hepatitis C was the most frequent cause of cirrhosis (54%). Our results show that hepatic hydrothorax was present with important ascites in 35 patients. Hydrothorax was significantly related to Child-Pugh C severity of cirrhosis (p=0.0001). Hydrothorax occurence was significantly associated with a low level of albumin (p=0.001), an important hyponatremia (p=0.001) and a low prothrombin rate (p=0.02). A therapeutic thoracentesis was performed in 57% of cases. Diuretics based on spironolactone and furosemide were indicated in 30 patients. Evolution was favorable in 19 patients. Refractory hepatic hydrothorax was present in 31 patients. Death, in the days which follow the hospitalisation, was in 13 patients. The 5-years survival rate was 60%. The mean survival time of patients with hepatic hydrothorax was 8.41 years against 10.75 years at patients without hepatic hydrothorax.

Conclusion: Hepatic hydrothorax is a common complication in our study. The improvement of the prognosis of our patients would require a better therapeutic management and especially the possibility of orthotopic liver transplantation which is the optimal therapeutic option for patients with hepatic hydrothorax.

Keywords:

Cirrhosis, hydrothorax, pleural effusion

##plugins.themes.academic_pro.article.details##

References

  1. Consigny Y. Complications pleuropulmonaires : comment traiter les complications Pleuropulmonaires. Gastroenterol Clin Biol. 2004;28:146-55.
  2. Cardenas A, Kelleher T, Chopra S. Review article: hepatic hydrothorax. Aliment Pharmacol Ther. 2004;20:271-9.
  3. Karen L, Krok MD, Cardenas A. Hepatic hydrothorax. Semin Respir Crit Care Med. 2012;33:3-10.
  4. Kinasewitz GT, Keddissi JI. Hepatic hydrothorax. Curr Opin Pulm Med. 2003; 9:261-5.
  5. Strauss RM, Boyer TD. Hepatic hydrothorax. Semin Liver Dis. 1997;17:227-32.
  6. Sahn SA, Heffner JE. Approach to the patient with pleurisy. In: Kelly WN, dir. Kelly's Textbook of Internal Medicine. Philadelphia: Lippincott, Williams and Wilkins; 1991.
  7. Ahmed RA, Marrie TJ, Huang JQ. Thoracic empyema in patients with community acquired pneumonia. Am J Med. 2006;119:877-83.
  8. Ben Ammar M. Pleurésies purulentes non tuberculeuses à propos de 46 observations[Thèse]. Pneumologie: Tunis; 1998. 110p
  9. Sboui L. Profil et aspects étiologiques des pleurésies. Revue analytique de 400 cas[Thèse]. Pneumologie. Tunis; 2004. 217p.
  10. Lazaridis KN, Frank JW, Krowka MJ, Kamath PS. Hepatic hydrothorax : pathogenesis, diagnosis, and management. Am J Med. 1999;107:262-7.
  11. Keddissi J, Eid AA, Janbey EM. Incidence and outcome of hydrothorax in patients with chronic liver disease. Chest. 2002;122:94S.
  12. Mirouze D, Juttner HU, Reynolds TB. Left pleural effusion in patients with chronic liver disease and ascites. Prospective study of 22 cases. Dig Dis Sci. 1981;26:984-8.
  13. Xiol X, Tremosa G, Castellote J, Gornals J, Lama C, Lopez C, Figueras J. liver transplantation in patients with hepatic hydrothorax. Transplant Int. 2005;18:672-5.
  14. Liu WL, Kuo PH, Ku SC, Huang PM, Yang PC. Impact of Therapeutic Interventions on Survival of Patients With Hepatic Hydrothorax. J Formos Med Assoc. 2010:109(8);582-8.
  15. El Atrache M, Abouljoud M, Sharma S, Abbass AA, Yoshida A, Kim D, Kazimi M, Moonka D, Brown K. Transjugular Intrahepatic Portosystemic Shunt following liver transplantation: can outcomes be predicted?. Clin Transplant. 2012:26;657-61
  16. Al-sharif H, Sharma S. Hepatic hydrothorax—how would you manage it? Can Respir J. 2005;12:440-2.
  17. Ibrisim D, Cakaloglu Y, Akyuz F. Treatment of hepatic hydrothorax with terlipressin in a cirrhotic patient. Scand J Gastroenterol. 2006;41:862-5.
  18. Barreales M, Saenz-Lopez S, Igarzabal A. Refractory hepatic hydrothorax: successful treatment with octreotide. Rev Esp Enferm Dig. 2005;97:830-5.
  19. Kalambokis G, Fotopoulos A, Economou M, Tsianos EV. Beneficial haemodynamic and renal sodium handling effects of compined milodrine and octreotide treatment in a cirrhotic patient with large hepatic hydrothorax and mild ascites. Nephrol Dial Transplant. 2005;20:2583.
  20. Takahashi K, Chin K, Sumi K, Sumi K, Nakamura T, Matsumoto H, Niimi A, et al. Resistant hepatic hydrothorax: a successful case with treatment by ncpap. Respir Med. 2005;99:262-4.
  21. McVay PA, Toy PT. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion. 1991;31(2):164-171.
  22. Boyer T. Transjugular intrahepatic portosystemic shunt: current status. Gastroenterology. 2003;124:1700-10.
  23. Gordon FD, Anastopoulos HT, Crenshaw W,et al. The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt. Hepatology. 1997;25:1366-9.
  24. Strauss RM, Martin LG, Kaufman SL, Boyer TD. Transjugular intrahepatic portal systemic shunt for the management of symptomatic cirrhotic hydrothorax. Am J Gastroenterol. 1994;89:1520-2.
  25. Siegerstetter V, Deibert P, Ochs A, Olschewski M, Blum HE, Rossle M. Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients. Eur J Gastroenterol Hepatol. 2001;13:529-34.
  26. Spencer EB, Cohen DT, Darcy MD. Safety and efficacy of transjugular intrahepatic portosystemic shunt creation for the treatment of hepatic hydrothorax. J Vasc Interv Radiol. 2002;13:385-90.
  27. Fidelman N, Kwan SW, LaBerge JM, Gordon RL, Ring EJ, Kerlan RK. The Transjugular Intrahepatic Portosystemic Shunt: an update. Am J Gastroenterol. 2012;199:746-55.
  28. Xiol X, Guadiola J. hepatic hydrothorax. Curr Opin Pulm Med. 1998;4:239.